Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab

Yanxiong Mao, Szilard Kiss, Julie L. Boyer, Neil R. Hackett, Jianping Qiu, Andrew Carbone, Jason G. Mezey, Stephen M. Kaminsky, Donald J. D'Amico, Ronald Crystal

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh.10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90±4% reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.

Original languageEnglish
Pages (from-to)1525-1535
Number of pages11
JournalHuman Gene Therapy
Volume22
Issue number12
DOIs
Publication statusPublished - 1 Dec 2011
Externally publishedYes

Fingerprint

Vascular Endothelial Growth Factor A
Dependovirus
Retinal Neovascularization
Costs and Cost Analysis
Macular Degeneration
Diabetic Retinopathy
Transgenic Mice
Bevacizumab
Epithelium
Monoclonal Antibodies
Pharmaceutical Preparations
Serogroup

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics

Cite this

Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. / Mao, Yanxiong; Kiss, Szilard; Boyer, Julie L.; Hackett, Neil R.; Qiu, Jianping; Carbone, Andrew; Mezey, Jason G.; Kaminsky, Stephen M.; D'Amico, Donald J.; Crystal, Ronald.

In: Human Gene Therapy, Vol. 22, No. 12, 01.12.2011, p. 1525-1535.

Research output: Contribution to journalArticle

Mao, Y, Kiss, S, Boyer, JL, Hackett, NR, Qiu, J, Carbone, A, Mezey, JG, Kaminsky, SM, D'Amico, DJ & Crystal, R 2011, 'Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab', Human Gene Therapy, vol. 22, no. 12, pp. 1525-1535. https://doi.org/10.1089/hum.2011.090
Mao, Yanxiong ; Kiss, Szilard ; Boyer, Julie L. ; Hackett, Neil R. ; Qiu, Jianping ; Carbone, Andrew ; Mezey, Jason G. ; Kaminsky, Stephen M. ; D'Amico, Donald J. ; Crystal, Ronald. / Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab. In: Human Gene Therapy. 2011 ; Vol. 22, No. 12. pp. 1525-1535.
@article{f1f327c4f5a2477eb15008754cc8d827,
title = "Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab",
abstract = "Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh.10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90±4{\%} reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.",
author = "Yanxiong Mao and Szilard Kiss and Boyer, {Julie L.} and Hackett, {Neil R.} and Jianping Qiu and Andrew Carbone and Mezey, {Jason G.} and Kaminsky, {Stephen M.} and D'Amico, {Donald J.} and Ronald Crystal",
year = "2011",
month = "12",
day = "1",
doi = "10.1089/hum.2011.090",
language = "English",
volume = "22",
pages = "1525--1535",
journal = "Human Gene Therapy",
issn = "1043-0342",
publisher = "Mary Ann Liebert Inc.",
number = "12",

}

TY - JOUR

T1 - Persistent suppression of ocular neovascularization with intravitreal administration of AAVrh.10 coding for bevacizumab

AU - Mao, Yanxiong

AU - Kiss, Szilard

AU - Boyer, Julie L.

AU - Hackett, Neil R.

AU - Qiu, Jianping

AU - Carbone, Andrew

AU - Mezey, Jason G.

AU - Kaminsky, Stephen M.

AU - D'Amico, Donald J.

AU - Crystal, Ronald

PY - 2011/12/1

Y1 - 2011/12/1

N2 - Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh.10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90±4% reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.

AB - Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of neovascular age-related macular degeneration and diabetic retinopathy. Bevacizumab, an anti-VEGF monoclonal antibody, is efficacious for these disorders, but requires monthly intravitreal administration, with associated discomfort, cost, and adverse event risk. We hypothesized that a single intravitreal administration of adeno-associated virus (AAV) vector expressing bevacizumab would result in persistent eye expression of bevacizumab and suppress VEGF-induced retinal neovascularization. We constructed an AAV rhesus serotype rh.10 vector to deliver bevacizumab (AAVrh.10BevMab) and assessed its ability to suppress neovascularization in transgenic mice overexpressing human VEGF165 in photoreceptors. Intravitreal AAVrh.10BevMab directed long-term bevacizumab expression in the retinal pigmented epithelium. Treated homozygous mice had reduced levels of neovascularization, with 90±4% reduction 168 days following treatment. Thus, a single administration of AAVrh.10BevMab provides long-term suppression of neovascularization without the costs and risks associated with the multiple administrations required for the current conventional bevacizumab monoclonal drug delivery.

UR - http://www.scopus.com/inward/record.url?scp=83455206223&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83455206223&partnerID=8YFLogxK

U2 - 10.1089/hum.2011.090

DO - 10.1089/hum.2011.090

M3 - Article

C2 - 21801028

AN - SCOPUS:83455206223

VL - 22

SP - 1525

EP - 1535

JO - Human Gene Therapy

JF - Human Gene Therapy

SN - 1043-0342

IS - 12

ER -